{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:25:00Z","timestamp":1793381100221,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s42770-023-01193-x","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T06:09:10Z","timestamp":1703225350000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime\/avibactam and ceftolozane\/tazobactam"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5477-4296","authenticated-orcid":false,"given":"Camila Soares","family":"Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4161-8355","authenticated-orcid":false,"given":"L\u00edbia Cristina Rocha Vilela","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5500-1129","authenticated-orcid":false,"given":"Jailton Lobo","family":"Da Costa Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4220-6889","authenticated-orcid":false,"given":"Maria Am\u00e9lia Vieira","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"issue":"6","key":"1193_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/QCO.0000000000000599","volume":"32","author":"A Burillo","year":"2019","unstructured":"Burillo A, Mu\u00f1oz P, Bouza E (2019) Risk stratification for multidrug-resistant Gram-negative infections in ICU patients. Curr Opin Infect Dis 32(6):583\u2013590","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"1193_CR2","first-page":"332","volume":"26","author":"H Rac","year":"2020","unstructured":"Rac H et al (2020) Evaluation of early clinical failure criteria for gram-negative bloodstream infections. Clin Microbiol Infect 26(3):332\u2013338","journal-title":"Clin Microbiol Infect"},{"key":"1193_CR3","doi-asserted-by":"publisher","unstructured":"Kaye SK, Pogue JM (2015) Infections caused by resistant gram-negative bacteria: epidemiology and management. https:\/\/doi.org\/10.1002\/phar.1636","DOI":"10.1002\/phar.1636"},{"key":"1193_CR4","doi-asserted-by":"publisher","unstructured":"Schneider EK, Reyes-Ortega F, Velkov T, Li J (2017) Antibiotic\u2013non-antibiotic combinations for combating extremely drug-resistant Gram-negative \u2018superbugs\u2019. https:\/\/doi.org\/10.1042\/EBC20160058","DOI":"10.1042\/EBC20160058"},{"key":"1193_CR5","doi-asserted-by":"publisher","unstructured":"Kanj SS, Kanafani ZA (2011) Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended spectrum \u03b2-lactamase\u2013producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant pseudomonas aeruginosahttps:\/\/doi.org\/10.4065\/mcp.2010.0674","DOI":"10.4065\/mcp.2010.0674"},{"key":"1193_CR6","doi-asserted-by":"publisher","unstructured":"Tiseo G, Brigante G, Giacobbe DR et al (2022) Diagnosis and management of infections caused by multidrug-resistant bact\u00e9ria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106611","DOI":"10.1016\/j.ijantimicag.2022.106611"},{"issue":"1","key":"1193_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-020-0685-1","volume":"9","author":"PY Chia","year":"2020","unstructured":"Chia PY et al (2020) The role of hospital environment in transmissions of multidrug-resistant gram-negative organisms. Antimicrob Resist Infect Control 9(1):1\u201310","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"1193_CR8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/antibiotics9070374","volume":"9","author":"R Cultrera","year":"2020","unstructured":"Cultrera R, Libanore M, Barozzi A et al (2020) Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant Gram-negative infections in immunocompetent patients: a single-center retrospective study. Antibiotics 9(7):374","journal-title":"Antibiotics"},{"issue":"5","key":"1193_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/jac\/dks523","volume":"68","author":"C Lucasti","year":"2013","unstructured":"Lucasti C et al (2013) Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68(5):1313\u20131323","journal-title":"J Antimicrob Chemother"},{"key":"1193_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CE.S40698","volume":"9","author":"P Lagac\u00e9-Wiens","year":"2014","unstructured":"Lagac\u00e9-Wiens P, Walkty A, Karlowsky JA (2014) Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evidence 9:13\u201325","journal-title":"Core Evidence"},{"issue":"20","key":"1193_CR11","first-page":"9266","volume":"16","author":"K Murano","year":"2008","unstructured":"Murano K et al (2008) Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg Med Chem 16(20):9266\u20139277","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"1193_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11908-018-0641-x","volume":"20","author":"L Nguyen","year":"2018","unstructured":"Nguyen L et al (2018) Multidrug-resistant pseudomonas infections: hard to treat, but hope in the horizon? Curr Infect Dis Rep 20(9):34\u201340","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"1193_CR13","first-page":"182","volume":"36","author":"B Balandin","year":"2021","unstructured":"Balandin B, Ballesteros D, Ruiz De Luna R et al (2021) Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Int J Antimicrob Agents 36(2):182\u2013187","journal-title":"Int J Antimicrob Agents"},{"key":"1193_CR14","doi-asserted-by":"publisher","unstructured":"Wilson GM, Fitzpatrick M, Walding K, et al (2021) Meta-analysis of clinical outcomes using ceftazidime\/ avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam for the treatment of multidrug-resistant gram-negative infections.https:\/\/doi.org\/10.1093\/ofid\/ofaa651","DOI":"10.1093\/ofid\/ofaa651"},{"key":"1193_CR15","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2020.909","author":"G Wilson","year":"2020","unstructured":"Wilson G, Fitzpatrick M, Walding K, Gonzale B, Evans C (2020) Meta-analysis of outcomes using ceftolozane-tazobactam and ceftazidime-avibactam for multidrug-resistant organism infections. Infect Control Hosp Epidemiol. https:\/\/doi.org\/10.1017\/ice.2020.909","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"1193_CR16","first-page":"101","volume":"25","author":"JA Karlowsky","year":"2021","unstructured":"Karlowsky JA et al (2021) In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017\u20132019. Braz J Infect Dis 25(1):101\u2013110","journal-title":"Braz J Infect Dis"},{"issue":"2","key":"1193_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bjid.2020.04.004","volume":"24","author":"FF Tuon","year":"2020","unstructured":"Tuon FF et al (2020) Evaluation of in vitro activity of ceftolozane\u2013tazobactam against recent clinical bacterial isolates from Brazil. Braz J Infect Dis 24(2):83\u201389","journal-title":"Braz J Infect Dis"},{"key":"1193_CR18","doi-asserted-by":"publisher","unstructured":"Tsivkovski R, Totrov M, Lomovskaya O (2020) Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother 64:e00130-20. https:\/\/doi.org\/10.1128\/AAC.00130-20","DOI":"10.1128\/AAC.00130-20"},{"key":"1193_CR19","doi-asserted-by":"publisher","unstructured":"Hirsch E, Brigman HV, Zuchi PC et al (2020) Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing enterobacterales clinical isolates from U.S. medical centres. https:\/\/doi.org\/10.1016\/j.jgar.2020.04.017","DOI":"10.1016\/j.jgar.2020.04.017"},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jgar.2017.06.008","volume":"10","author":"H Barrios","year":"2017","unstructured":"Barrios H, Garza-Ramos U, Mejia-Miranda I, Reyna-Flores F, Sanchezperez A, Mosqueda-Garcia D, Silva-Sanchez J (2017) Bacterial resistance consortium ESBL-producing escherichia coli and klebsiella pneumoniae: the most prevalent clinical isolates obtained between 2005 and 2012 in Mexico. J Glob Antimicrob Resist 10:213\u2013218","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"1193_CR21","first-page":"56","volume":"27","author":"TN Carvalho","year":"2023","unstructured":"Carvalho TN et al (2023) Evaluation of in-vitro susceptibility of \u00df-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil. Braz J Infect Dis 27(1):56\u201361","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"1193_CR22","first-page":"480","volume":"50","author":"F Rossi","year":"2017","unstructured":"Rossi F et al (2017) The in vitro activity of ceftazidime\u2013avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in S\u00e3o Paulo, Brazil. Rev Soc Bras Med Trop 50(4):480\u2013483","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"1193_CR23","first-page":"274","volume":"65","author":"L Cheng","year":"2016","unstructured":"Cheng L et al (2016) Clonal dissemination of KPC-2 producing Klebsiella pneumoniae ST11 clone with high prevalence of oqxAB and rmtB in a tertiary hospital in China: results from a 3-year period. J Med Microbiol 65(3):274\u2013280","journal-title":"J Med Microbiol"},{"key":"1193_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-12-22","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Temperoni C, Astilean A (2013) New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. https:\/\/doi.org\/10.1186\/1476-0711-12-22","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1193_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120912049","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Peghin M (2020) How to manage KPC infections. Ther Adv Infect Dis. https:\/\/doi.org\/10.1177\/2049936120912049","journal-title":"Ther Adv Infect Dis"},{"issue":"10","key":"1193_CR26","first-page":"5736","volume":"60","author":"S Nath","year":"2017","unstructured":"Nath S et al (2017) In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 60(10):5736\u20135741","journal-title":"Antimicrob Agents Chemother"},{"key":"1193_CR27","first-page":"192","volume":"18","author":"L Onorato","year":"2019","unstructured":"Onorato L et al (2019) Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. J Glob Antimicrob Resist 18:192\u2013198","journal-title":"J Glob Antimicrob Resist"},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00134-015-3719-z","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti M et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776\u2013795","journal-title":"Intensive Care Med"},{"key":"1193_CR29","doi-asserted-by":"publisher","unstructured":"Tsuji BT et al (2019) Therapeutic strategies for infections by Klebsiella pneumoniae carbapenem resistant: a narrative review. https:\/\/doi.org\/10.33448\/rsd-v11i7.30296","DOI":"10.33448\/rsd-v11i7.30296"},{"key":"1193_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02291-19","author":"SJJ Jorgensen","year":"2020","unstructured":"Jorgensen SJJ et al (2020) Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02291-19","journal-title":"Antimicrob Agents Chemother"},{"key":"1193_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgar.2020.10.023","volume":"23","author":"H Kuang","year":"2020","unstructured":"Kuang H et al (2020) Characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime\/avibactam. J Glob Antimicrob Resist 23:119\u2013124","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"1193_CR32","first-page":"306","volume":"43","author":"R Zaragoza","year":"2020","unstructured":"Zaragoza R et al (2020) Update of the treatment of nosocomial pneumonia in the ICU. Med Intensiva 43(5):306\u2013326","journal-title":"Med Intensiva"},{"key":"1193_CR33","first-page":"193","volume":"23","author":"M Meschiari","year":"2020","unstructured":"Meschiari M et al (2020) Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. J Glob Antimicrob Resist 23:193\u2013196","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"1193_CR34","first-page":"6","volume":"11","author":"J Gorham","year":"2022","unstructured":"Gorham J, Fs T, Hites M (2022) Drug regimens of novel antibiotics in critically Ill patients with varying renal functions: a rapid review. Antibiotics 11(1):6","journal-title":"Antibiotics"},{"issue":"7","key":"1193_CR35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2146\/ajhp140161","volume":"72","author":"D Cluck","year":"2015","unstructured":"Cluck D, Lewis P, Stayer B, Spivey J, Moorman J (2015) Ceftolozane-tazobactam: uma cefalosporina de nova gera\u00e7\u00e3o. Am J Health Syst Pharm 72(7):525\u2013536","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"1193_CR36","first-page":"1088","volume":"55","author":"A Xiao","year":"2015","unstructured":"Xiao A, Miller B, Huntington J, Nicolau D (2015) Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 55(9):1088\u20131095","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1193_CR37","first-page":"269","volume":"51","author":"L Barcelona","year":"2020","unstructured":"Barcelona L, Nemirovsky C, L\u00f3pez FMJ, De Vedia L (2020) Nuevos antibi\u00f3ticos en la era de la multiresistencia: revisi\u00f3n sobre ceftolozano\/tazobactam y ceftazidima\/avibactam. Rev Argent Microbiol 51(3):269\u2013276","journal-title":"Rev Argent Microbiol"},{"issue":"8","key":"1193_CR38","first-page":"1298","volume":"44","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J et al (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Crit Care Med 44(8):1298\u20131304","journal-title":"Crit Care Med"},{"issue":"3","key":"1193_CR39","first-page":"844","volume":"53","author":"JD Lutgring","year":"2016","unstructured":"Lutgring JD, Limbago BM (2016) The problem of carbapenemase-producing-carbapenem-resistant-enterobacteriaceae detection. J Clin Microbiol 53(3):844\u2013850","journal-title":"J Clin Microbiol"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-023-01193-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T06:11:29Z","timestamp":1709878289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-023-01193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s42770-023-01193-x","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"value":"1517-8382","type":"print"},{"value":"1678-4405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this article declare that they have no conflict of interest that\u00a0could interfere with the impartiality of the scientific work. Furthermore no competing financial interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}